×

Analyst on FDA vs. Sarepta: Approval going against the odds

2:48 PM ET Tue, 26 April 2016

Liisa Bayko, JMP Securities Biotech Analyst and Managing Director, discusses the FDA's rejection of fast-track approval of Sarepta's Duchenne muscular dystrophy drug.